Young Investigator Award (YIA)
MOASC Cary Presant Young Investigator Award
The Young Investigator Award (YIA) aims to support early-career researchers, typically those within a few years of having completed their postgraduate training, who are focused on innovative research in clinical and translational oncology. By offering support tailored to early-career researchers, YIA programs play a crucial role in fostering talent, promoting innovation, and advancing the fight against cancer through cutting-edge research. The proposed research project should be a new project intended to support clinical and translational oncology research. Projects should account for the 1-year term of the grant and the funding allocation provided, and will be assessed based on academic merit and feasibility. The final funding decision will be made by the MOASC Board of Directors.
$25,000 to accelerate clinical & translational oncology—1-year term
Applicant Eligibility
-
Hold an MD or DO degree with an intent to practice clinical oncology
-
Have initiated or completed an ACGME-accredited fellowship program in hematology and/or oncology
-
Be no more than seven years beyond completion of fellowship training
-
Practice at a Southern California institution for the full duration of the one-year award
Award at a Glance
-
Award: $25,000
-
Number of Awards: One
-
Grant Term: July 1, 2027 – June 30, 2028
-
Focus: Clinical & Translational Oncology
-
Application Deadline: November 6, 2026
-
Award Decision: February 8, 2027
-
Award Presentation: March 20, 2027
ABOUT CARY PRESANT, MD
The Young Investigator Award is named in honor of Cary Presant, MD, founder and first president of the Medical Oncology Association of Southern California.
Dr. Presant's longstanding leadership and commitment to oncology have helped shape MOASC and its mission to advance cancer care through education, collaboration, research, and professional engagement. He continues to serve on the MOASC Board of Directors today. The Cary Presant, MD Young Investigator Award carries that commitment forward by investing in promising investigators and innovative oncology research.
How to Apply
Email the entire application as a single PDF to [email protected] by Friday, November 6, 2026.
Supported by a grant from AVEO Oncology (“AVEO”), an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
